Audio Medica News
Audio Journal of Oncology PodcastEpisodes
Episodes of Audio Journal of Oncology Podcast
Mark All
Search Episodes...
BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United Kingdom and Nigeria. A range of low cost communi
Audio Journal of Oncology, February 14 2023, Reporting from the American Society of Hematology Annual Meeting (ASH), December 2022An interview with Amy A. Kirkwood MSc, Senior Statistician at the Cancer Research UK & UCL Cancer Trials Centre
Interview with Matthias Stelljes MD, Head of the Allogeneic Stem Cell Program at the University of Münster, GermanyNEW ORLEANS, USA—For your patients with acute myeloid leukemia (AML) the benefit of prompt allogeneic hematopoietic cell trans
Ibrutinib Enables Transplant-Free Therapy for Mantle Cell LymphomaNEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best practice recommendations) could be treated as
January 10, 2023Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple MyelomaINTERVIEW WITH:Ajai Chari MD, Associate Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program at
An interview with: Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, from the Yonsei Cancer Center at Yonsei University College of Medicine in Seoul, South Korea.BARCELONA, Spain—A “next generation” ROS1 tyrosine kinase inhibitor (TKI), re
ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic TherapyBARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine kinase—mutated in some cancers—were reporte
Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One StudyBARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study r
BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and actual mechanisms for cancer inhibition. But it now lo
New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma Interview with:Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona at Barcelona University, Spain.BARCELONA, S
PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immunotherapy. This finding came from a phase th
BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeuti
PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard p
Audio Journal of Oncology: October, 2022:Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer TherapyAndré Pfob, Clinical Research Assistant in the University Breast Unit of Heidelberg University Hospital, Germany tells th
HEIDELBERG, Germany—André Pfob, Clinical Research Assistant from the University Breast Unit at Heidelberg University Hospital, Germany tells the Audio Journal of Oncology’s correspondent Peter Goodwin about the machine learning techniques his
PARIS, France—Long remissions and “potential cures” were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancers expressing the BRCA mutation who were tre
ATLANTA, USA—A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into acute myeloid leukemia.Findings from Oxford University in the UK (usin
PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ES
CAMBRIDGE, UK—The Audio Journal of Oncology relays this interview from the Oncology Times Podcast: OncTimesTalk. Peter Goodwin visited genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, Universi
UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Journal of Medicine that supports the widespread i
Second Study Confirms Lung Cancer CT Screening Cuts DeathsNETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viability of computed tomographic (CT) screening for
Audio Journal of OncologySAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergrou
Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation The Audio Journal of Oncology PodcastSAN DIEGO—Overall survival after allogeneic hematopoietic cell transplantation (allo-HCT) was found to be adversely
Audio Journal of OncologyReporting from 2018 annual meeting of the American Society of HematologyINTERVIEW WITH: John C. Byrd MD, Chief Medical Officer for the “Beat AML Trial” , Chair of Leukemia Research,  Senior Advisor for Cancer Exper
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinas
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us